Mytos builds robots for manufacturing human cells. Operators input stem cells, and our platform turns them into specific cells such as neurons and heart cells over multiple weeks.
Mytos is a Y Combinator company in the Summer 2018 batch. Its directory entry describes it as: Robotic human cell manufacturing. The founders listed are Ali Afshar (Founder/CEO), Ignacio Willats (Founder) (Y Combinator directory entry, May 3, 2018).
Get an email when Mytos changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
Mytos builds robots for manufacturing human cells. Operators input stem cells, and our platform turns them into specific cells such as neurons and heart cells over multiple weeks.
Last year, patients were cured of Parkinson’s, vision loss, and Type 1 diabetes using stem-cell derived cells. We need 1000x the global capacity to produce these cells, and treat millions of patients. But today these Regenerative Medicines are produced by hand, meaning they’re too expensive and don’t scale.
Mytos has fully automated production of these cells, making it scalable. We have our first manufacturing deal - neurons for treating Parkinson’s - and we’re in conversations with majority of the other top players.
Ali Afshar
Founder/CEO
Ignacio Willats
Founder
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
One of 34 companies held here in Healthcare › Industrial Bio.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Want the whole picture on Mytos?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Mytos: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mytos covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Mytos: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
